Carcinoma, Non-Small-Cell Lung
Showing 26 - 50 of 574
NSCLC, Epidermal Growth Factor Receptor, Leptomeningeal Metastasis Trial (Pemetrexed)
Not yet recruiting
- Carcinoma, Non-Small-Cell Lung
- +2 more
- (no location specified)
Mar 27, 2023
Solid Tumor, Haematological Malignancy, Melanoma Trial in United Kingdom (Vemurafenib, Cobimetinib)
Recruiting
- Solid Tumor
- +11 more
-
Belfast, United Kingdom
- +16 more
Mar 2, 2023
Circulating Tumor DNA and T Cell Repertoire Predict
Not yet recruiting
- Carcinoma, Non-Small-Cell Lung
- Brain Metastases
- Whole-brain radiotherapy
-
Wuhan, Hubei, ChinaUnion hospital
Feb 12, 2023
NSCLC Trial in Washington, Hackensack, Neptune (Nivolumab, Ipilimumab, Carboplatin)
Not yet recruiting
- Carcinoma, Non-Small-Cell Lung
- Nivolumab
- +4 more
-
Washington, District of Columbia
- +2 more
Jan 27, 2023
NSCLC, NSCLC, Carcinoma, Bronchogenic Trial in Worldwide (Furmonertinib)
Recruiting
- Non-Small Cell Lung Cancer
- +14 more
-
Glendale, California
- +12 more
Feb 2, 2023
NSCLC, Non-Small Cell Lung Carcinoma, NSCLC Trial run by the National Cancer Institute (NCI) (biological, drug, device)
Not yet recruiting
- Non-Small Cell Lung Cancer
- +3 more
- Montanide (Registered Trademark) ISA-51 VG Adjuvant
- +3 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Feb 2, 2023
NSCLC Trial in Worldwide (Lazertinib, Amivantamab, Carboplatin)
Recruiting
- Carcinoma, Non-Small-Cell Lung
- Lazertinib
- +3 more
-
Los Angeles, California
- +83 more
Jan 31, 2023
NSCLC Trial in Worldwide (Amivantamab, Pemetrexed, Carboplatin)
Active, not recruiting
- Carcinoma, Non-Small-Cell Lung
- Amivantamab
- +2 more
-
Duarte, California
- +228 more
Jan 31, 2023
NSCLC Trial in Worldwide (Dexamethasone, Montelukast, Methotrexate)
Not yet recruiting
- Carcinoma, Non-Small-Cell Lung
- Dexamethasone
- +4 more
-
Fountain Valley, California
- +17 more
Jan 31, 2023
NSCLC Trial in Japan, Korea, Republic of, Singapore (capmatinib, pemetrexed, cisplatin)
Terminated
- Carcinoma, Non-Small-Cell Lung
- capmatinib
- +4 more
-
Kashiwa, Chiba, Japan
- +3 more
Jan 31, 2023
NSCLC, EGF-R Positive NSCLC Trial in Wuxi (Parimparib, Chemotherapy drug, Targeted Therapy Agent)
Recruiting
- Carcinoma, Non-Small-Cell Lung
- EGF-R Positive Non-Small Cell Lung Cancer
- Parimparib
- +2 more
-
Wuxi, Jiangsu, ChinaAffiliated Hospital of Jiangnan University
Jan 30, 2023
NSCLC Trial in Worldwide (Nivolumab, Carboplatin, Cisplatin)
Active, not recruiting
- Carcinoma, Non-Small-Cell Lung
- Nivolumab
- +6 more
-
Tampa, Florida
- +112 more
Jan 30, 2023
NSCLC Trial in Marietta, Taichung City, Tainan (Sacituzumab Govitecan, Pembrolizumab)
Recruiting
- Carcinoma, Non-Small-Cell Lung
- Sacituzumab Govitecan
- Pembrolizumab
-
Marietta, Georgia
- +2 more
Jan 27, 2023
NSCLC Trial in Worldwide (Entrectinib, Crizotinib)
Recruiting
- Carcinoma, Non-Small-Cell Lung
-
Barretos, SP, Brazil
- +66 more
Jan 27, 2023
NSCLC Trial in Worldwide (Alectnib, Cisplatin, Vinorelbine)
Active, not recruiting
- Carcinoma, Non-Small-Cell Lung
- Alectnib
- +5 more
-
Chicago, Illinois
- +140 more
Jan 20, 2023
NSCLC Trial in Worldwide (Sasanlimab Prefilled syringe, Encorafenib, Binimetinib)
Active, not recruiting
- Carcinoma, Non-Small-Cell Lung
- Sasanlimab Prefilled syringe
- +5 more
-
Duarte, California
- +96 more
Jan 18, 2023
NSCLC Trial in Worldwide (CC-486, Pembrolizumab, Placebo)
Active, not recruiting
- Carcinoma, Non-Small-Cell Lung
- CC-486
- +2 more
-
Glendale, Arizona
- +33 more
Jan 12, 2023
KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small Cell Lung, NSCLC Trial (JDQ443, trametinib, Ribociclib)
Recruiting
- KRAS G12C Mutant Solid Tumors
- +10 more
- JDQ443
- +3 more
-
Boston, Massachusetts
- +5 more
Jan 11, 2023
NSCLC Trial in Amsterdam (Ipilimumab, Cemiplimab, SBRT)
Recruiting
- Carcinoma, Non-Small-Cell Lung
- Ipilimumab
- +2 more
-
Amsterdam, Noord-Holland, NetherlandsAntoni van Leeuwenhoek - Netherlands Cancer Institute
Jan 10, 2023
NSCLC Trial in Worldwide (Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Docetaxel)
Completed
- Carcinoma, Non-Small-Cell Lung
- Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody
- Docetaxel
-
Beijing, China
- +37 more
Jan 9, 2023